




# Mötesetikett

- Digitalt möte - alla mikrofoner avstängda
- Under presentationen, ställ dina frågor i chatten. Utvalda frågor tas upp vid avsedd tid i agendan av chatt-ansvarig.
- Chatten används enbart för frågor, ingen diskussion, med hänsyn till den som presenterar
- Använd handuppräkningsfunktionen och sätt gärna på kameran vid frågor under den sista frågestunden
- Presentationen kommer att delas i efterhand, via kalendarier





# Horizon Europe

Framework programme for research and innovation 2021–2027



# Today

---

10:00 Welcome

Part 1: The European Partnerships in Health

Part 2: The Mission on Cancer

Part 3: Cluster 1, Health

12:00 Closing




---

Horizon Europe is a  
**POLITICAL INSTRUMENT**  
where research and  
innovation are needed to  
achieve the defined priorities.



# Horizon Europe



# Why participate?

- Development of cutting-edge ideas – **what is YOUR Cutting edge?**
- Access to new knowledge, skills and markets – **whom do I need to work with?**
- Strategic partnerships and collaborations – **anyone missing in the consortium?**
- Access to advanced technologies and methods – **how can I secure this?**
- Solutions to global challenges – **Am I addressing the scope?**
- **Am I only doing it for the money?**



# European partnerships in Health



# Horizon Europe Partnerships



European Commission



EU Industry



Member states

Horizon Europe

**EU Partnership**

National programmes

Implement European strategies, accumulate funding and leverage national activities, long-term 7 to 10 years

Calls, needs and gaps, capacity building, networking activities, exchange of knowledge and best practices, translating research results into practical benefit



# How does a Joint Transnational Call (typically) work?


- The member funders agrees on the topic for the call and organise the call together
- Usually multilateral consortia
- Each partner is funded by their national funder. National rules apply
- All funders don't participate in all calls
- Co-funding from the European Commission



VINNOVA

FORTE

FORMAS



VINNOVA



## EP PerMed

European Partnership  
for **Personalised Medicine**

Improved Health  
outcomes

Equal access to  
sustainable  
healthcare

Research

Implementation

Competitiveness  
and accelerated  
uptake of PM  
solutions

Europe at the  
forefront of  
R&I for PM

Innovation

Definition Personalised Medicine:

[https://ec.europa.eu/info/research-and-innovation/research-area/health-research-and-innovation/personalised-medicine\\_en](https://ec.europa.eu/info/research-and-innovation/research-area/health-research-and-innovation/personalised-medicine_en)



# R&I calls within EP PerMed covering a larger portion of the value generation circle

Other activities:

- Summer schools
- Hackathon
- Best practise examples
- Conferences (Berlin Feb 11-12)
- Etc.




Image adapted from EIT Health.  
Technology (TRL). Business (BRL), Health Care (CRL)

# Call EP PerMed JTC 2025:

## “Pharmacogenomic strategies for personalized medicine approaches (PGxPM2025)”

Application deadline Feb 18 14:00 CET 2025,  
Swedish funder Vinnova

- Partnering tool: [Home | EP PerMed Partnering Platform](#)
- Recording of international info-meeting here: [EP PerMed JTC2025 Information Day - European Partnership for Personalised Medicine - EP PerMed](#)




Bild: EP PerMed

[EP PerMed Joint Transnational Call \(JTC\) 2025 - European Partnership for Personalised Medicine - EP PerMed](#)



# Aim of the JTC2025

Funding of Research projects in human health on **pharmacogenomic strategies for PM approaches** address **one or more** of the following aspects:

- 🎯 **Identification of new pharmacogenomic markers or signatures** using (multi)-omics data in relation to drug or drug combination.
- 🎯 **Validation of a pharmacogenomic marker or signatures** using (multi)-omics data in predicting drug or drug combination outcomes.
- 🎯 **Use pharmaco-omics strategies** to determine the right dosage, the efficacy of treatments and/or the risk of adverse drug response and non-response to treatment **to tailor personalised treatment pathways**, including combined treatments (multi medication).

# EP PerMed: 1<sup>st</sup> **Fast Track & Venture Creation** Future Networking Call



The EP PerMed **Fast Track** Validation Programme aims to accelerate the development and adoption of innovative PM solutions in 2025, fostering advancements that can transform healthcare and improve patient outcomes.

More information: <https://www.eppermed.eu/funding-projects/calls/fast-track-call/>  
[EP PerMed Fast Track Call: Webinar Recordings online - European Partnership for Personalised Medicine - EP PerMed](#)

The EP PerMed **Venture Creation** Programme will provide guidance by experienced mentors, ensuring that each project is mentored on its journey. By equipping researchers with robust business validation techniques and strategic insights, we guide them so their pioneering work can reach the market effectively.

**Webinar: 28 January 2025, 11am – 12pm CET.**

More information: <https://www.eppermed.eu/funding-projects/calls/venture-creator/>

[Networking Support Call \(NSC\) 2025 - European Partnership for Personalised Medicine - EP PerMed](#)





# ERDERA aim to improve the health and well-being of 30 million people living with a rare disease in Europe

Joint Transnational Calls – interdisciplinary research calls  
Clinical Trials Call  
Networking Support Scheme

# Call ERDERA JTC 2025:

**“Pre-clinical therapy studies for rare diseases using small molecules and biologicals – development and validation”**

**Application deadline Feb 13 14:00 CET,  
Swedish funder Vinnova**



Bild: ERDERA

[Internationella prekliniska terapistudier inom sällsynta sjukdomar | Vinnova](#)

[Funding - ERDERA ERDERA - European Rare Diseases Research Alliance](#)

# Aim of the call

- Support interdisciplinary, transnational collaborations that leverage complementary expertise to develop new therapies for rare diseases.
- Research projects should focus on pre-clinical studies involving small molecules or biologicals. This could include the development of novel therapies, biomarkers for therapy efficiency, or replication of pre-clinical studies to validate findings.
- Eligible proposals may include research on:
  - Development of pre-clinical therapies using cell, organoid, or animal models.
  - Biomarker identification that correlates with therapeutic efficacy.
  - Pre-clinical proof-of-concept studies showing pharmacological activity and safety data.



# THCS Expected outcomes

**Stronger local and regional ecosystems**

**Researchers engaged in collaborative research at international level**

**H&C authorities and policy makers use research results in decision making**

**Better cooperation among Countries in this R&I field**

**H&C authorities, policymakers plan and carry out efficient investments**

**H&C providers and professionals implement innovative solution**




## JTC 2025 - "Better care closer to home"

The third JTC addresses the need to improve the **enhancement of primary and community care**, provide **policy and decision makers** with the necessary **knowledge and tools** to govern the transitions needed in these sectors.

The ultimate goal is to improve **health and care system** dimensions such as **quality, efficiency, equity, and sustainability**.



# Submission and Evaluation Procedure





# JPND: Joint programme- Neurodegenerative Disease Research

- JPND is a so-called ERA-NET Cofund under the previous framework programme Horizon2020
- During 2025-2026 JPND will transit into the partnership BrainHealth
- Vetenskapsrådet and Forte are members of JPND and have expressed interest to join BrainHealth



# JPND call 2025

## Health and social care research with a focus on the moderate and late stages of neurodegenerative diseases


**Aim: Improving the well-being of people with neurodegenerative diseases through social sciences and humanities research.**

- Increase understanding of the factors that hamper social inclusion, civic participation, dignity and quality of life of patients and their families
- Develop more adequate concepts of easily accessible support



# JPND call 2025

Health and social care research with a focus on the moderate and late stages of neurodegenerative diseases



Parties from at least three different countries and a maximum of two participants from the same country.


Need to adequately involve patients, carers, and the public as research participants

Swedish participation through Forte, please read about Swedish-specific procedures [here](#).

Swedish contact person: [isabelle.monell@forte.se](mailto:isabelle.monell@forte.se)





# GH-EDCTP3-JU



- **Global Health - European & Developing Countries Clinical Trials Partnership – Joint Undertaking**
- EDCTP3 is an institutionalised partnership and the calls are announced in the [Funding & Tenders portal](#).
- Focus on infectious diseases in sub-Saharan Africa
- Research, capacity strengthening and implementation of interventions

# EDCTP3 call topics 2025



[HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage](#): Global collaboration action for the development of vaccines for reducing the disease burden of Tuberculosis in sub-Saharan Africa (RIA)

[HORIZON-JU-GH-EDCTP3-2025-01-MALARIA-02-two-stage](#): Global collaboration action for research on existing Malaria therapeutics and clinical development of new antimalarial candidates (RIA)

[HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage](#): Accelerating the development of prophylactic vaccines against Neglected Tropical Diseases (NTDs) in sub-Saharan Africa (RIA)

[HORIZON-JU-GH-EDCTP3-2025-02-FELLOW-01-two-stage](#): Global Health EDCTP3 JU and contributing partners funded Strategic Training Hubs for Fellowships in Public Health covering Biostatistics, Epidemiology and Modelling (CSA)

[HORIZON-JU-GH-EDCTP3-2025-03-NETWORKS-01-two-stage](#): Global collaborative action for strengthening the Regional Networks of Excellence and Epidemic Preparedness Consortia (CSA)



# Additional health partnerships


- **IHI** - Innovative Health Initiative  
Specific info session on 21 January



- **GACD**- Global Alliance for Chronic Diseases  
Call on [Strengthening Health Systems](#) will open in February but it's not decided if the EC will join.



- **PARC** - Partnership for the Assessment of Risks from Chemicals  
No open calls but still possible to engage



- **ERA4Health**  
Ongoing call on investigator-initiated clinical studies but no Swedish funders participate



# Forthcoming health partnerships

- **EUP OHAMR** - European Partnership One Health Antimicrobial Resistance  
First call expected in the end of 2025



- **BE READY NOW** European partnership for pandemic preparedness  
First call expected early 2026



- **BrainHealth**  
First call expected early 2026





# Mission Cancer



# Mission areas

Missions are not only about R&I – focused on delivering a public good.

They are used to agree on a European level what we want to change and deliver it in society.

1



**Adaptation to  
Climate Change,  
including Societal  
Transformation**

2



**Cancer**

3



**Healthy Oceans,  
Seas, Coastal and  
Inland Waters**

4



**Climate-Neutral and  
Smart Cities**

5



**Soil Health and  
Food**

# Mission Cancer

improving the lives of more than 3 million people by 2030 through prevention, cure and for those affected by cancer including their families, to live longer and better



#### 4 objectives:

1. Understand Cancer
2. Prevention and early detection
3. Diagnosis and treatment
4. Quality of life for patients and survivors

#### 5 transversal priorities:

1. Equitable access
2. Childhood cancer
3. Innovation
4. Personalised medicine
5. Citizen engagement

# Implementation of Mission Cancer

Two "intertwined" EU initiatives





# Mission-driven approach ?

- Cancer as a societal challenge.
- Cross sectorial and multidisciplinary, even at governance level.
- Focus on synergies and some strategic actions aiming at structuring Cancersystem at EU and national levels.
- New calls build on previous and ongoing initiatives ([Implementation Plan](#))



# Mission Cancer

- Sjukvården och forskning kommer närmare
- Samverkan med nya grupperingar som tar fram rätt lösningar snabbt



# Varför cancer?

- En pilot som bygger upp förmåga och infrastruktur
- Ett område med redan stort engagemang







# Cancer Mission: flagship initiatives



Understand

ACCESS

**Uncan.eu:** aiming at improving understanding of cancer mechanisms



Prevention

EQUITABLE

**European Cancer Prevention Centre:** aiming at providing evidence on cancer prevention



Diagnostic & treatment


ENSURE

**Network of Comprehensive Cancer Infrastructures:** aiming at strengthening research capacities of CCIs



Support QoL

**European Cancer Patient Digital Centre:** aiming at supporting QoL of patients






# UNCAN

European Initiative to Understand Cancer

**Syfte:** En europeisk federerad plattform för tillgång, delande och analys av genererad hälsodata.

En blueprint har tagits fram och publicerats på [UNCAN.eu](https://uncan.eu).

Uppbyggnaden av plattformen kommer utlysas i nästa arbetsprogram.



# ECPDC

## European Cancer Patient Data Centre

**Syfte:** Öka levnadskvalitén för cancerpatienter, överlevare och familjer via nationella datanoder med digitala tjänster.

Uppbyggnaden av portalen kommer utlysas i kommande arbetsprogram.

Information and support for cancer patients, survivors and their families

Access to clinical data and sharing (incl. cross-border portability)

Tool for patient-reported outcome data collection and sharing

Empowerment of patients: Data donation and tools for participating in research

# Cancer Mission Hub

The Coordination Support Action ECHoS is developing methods and guidelines for National Cancer Mission Hubs to gather and involve relevant stakeholders, in cancer-related policy dialogues.

National Cancer Mission Hubs are being established in Member States, and SE is planning for a Swedish version adapted to the Swedish context.

Contact: [cancer@socialstyrelsen.se](mailto:cancer@socialstyrelsen.se)



# Workprogramme 2025



# Stöd från Vinnova


- Kontakta NCPer med frågor
  - Jonathan Nylander, NCP EU Missions  
[jonathan.nylander@vinnova.se](mailto:jonathan.nylander@vinnova.se)
- Få mejlutskick om Mission Cancer
- Planeringsbidrag inför internationell ansökan.
- Samarbeta internationellt inom hälsa | Vinnova






# Cluster 1 – Health

# Horizon Europe





# Horizon Europe from here



WP 2025

WP 2026/27



# Priorities according to the strategic plan 2025-27

- Staying healthy in a rapidly changing society
- Living and working in a health-promoting environment
- Tackling diseases and reducing disease burden
- Ensuring equal access to innovative, sustainable, and high-quality healthcare
- Developing and using new tools, technologies and digital solutions for a healthy society
- Maintaining an innovative, sustainable, and competitive EU health industry



# Topic text – the devil in the details

**Topic type:** RIA, IA, CSA – does it match my project plans?


**Topic description:** expectations from the project  
(expected outcomes, expected impacts and cross-cutting priorities)

**Important to think about, but even more  
important to put in writing!**

Excellens, impact, genomförning



# Proposal timeline





# Summary



# Resources

# Ways to find information

## Vinnovas microsite on international opportunities in health and life science

- Contains links to relevant EU programmes, information meetings and related national funding

## Funding and Tenders portal

- Contains all texts (open, upcoming and closed calls)
- Contains links under each topic
  - to related legal documents
  - to FAQ related to each topic

## Reference documents page

- Contains all texts collected in work programmes
- Contains all legal documents sorted by programme



# Horizon Europe support

## EUSME support office

- Supports Swedish SMEs to find and understand funding opportunities under Horizon Europe
- Supports SME applicants with their application

## National contact points (NCPs)

- Contact details to all Swedish NCPs can be found on Vinnovas website (see link above)
- Support all organisations, including SMEs, in finding and understanding funding opportunities under Horizon Europe and related programmes
- Support all organisations in legal and financial issues related to Horizon Europe

## Q&A function on Funding and Tenders portal

- Digital form to ask programme-related questions directly to the EC

# Financial support when preparing an application

[Planning grant for international proposals 2025](#) – Vinnova



## What can you apply for?

Development of a proposal for a research and innovation project to an international call for proposals.

Activities that strengthen and develop a proposal into an international call for proposals. The planning project may last for maximum 12 months.



## Who can apply?

Swedish actors from academia, research institutes, public sector, civil society or small and medium-sized enterprises (SMEs) who prepare a proposal for a research - and innovation projects to an international call for proposals.



## How much can you apply for?

Up to SEK 300,000 for actors who plan to apply in an international call for proposals. Up to SEK 500,000 for actors who plan to coordinate an international project with at least 3 actors from 3 different countries.



**Lycka till! Och hör av dig.**



# More information available

## EP PerMed

EP PerMed Contact person (Vinnova) [malin.eklund@vinnova.se](mailto:malin.eklund@vinnova.se); [casper.ullsten-wahlund@vinnova.se](mailto:casper.ullsten-wahlund@vinnova.se)

## ERDERA

ERDERA Contact person (Vinnova) [anna-carin.christoffersson@vinnova.se](mailto:anna-carin.christoffersson@vinnova.se)

## THCS

THCS Contact person (Forte) [staffan.arvidsson@forte.se](mailto:staffan.arvidsson@forte.se)

**For partnerships in other parts of the portfolio**, please see [ERA Learn](#)

To learn about other partnerships in parts of the [portfolio](#) other than health, contact the respective secretariate directly, or contact the respective cluster NCP: [Kontakt för Horisont Europa | Vinnova](#)

## JPND

- General: <https://neurodegenerationresearch.eu/>
- Call 2025: [Health and social care research with a focus on the moderate and late stages of neurodegenerative diseases](#)
- Forte: <https://forte.se/utlysning/internationell-utlysning-jpnd-2025/> Contact person: [isabelle.monell@forte.se](mailto:isabelle.monell@forte.se)

## EDCTP3

- General: [https://www.global-health-edctp3.europa.eu/index\\_en](https://www.global-health-edctp3.europa.eu/index_en)
- Calls opening 30 january:  
[HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage](#)  
[HORIZON-JU-GH-EDCTP3-2025-02-FELLOW-01-two-stage](#)  
[HORIZON-JU-GH-EDCTP3-2025-03-NETWORKS-01-two-stage](#)  
[HORIZON-JU-GH-EDCTP3-2025-01-MALARIA-02-two-stage](#)  
[HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage](#)

## European Partnership on Metrology Health Call 2025

- Currently open, Closing 17 February 2025 - 23:59 CET  
[Health Call 2025 S1](#)

# Links to other partnerships in the Health portfolio

[IHI - Innovative Health Initiative](#)

[GACD- Global Alliance for Chronic Diseases](#)

[PARC - Partnership for the Assessment of Risks from Chemicals](#)

[ERA4Health](#)

[EUP OHAMR - European Partnership One Health Antimicrobial Resistance](#)

[BE READY NOW European partnership for pandemic preparedness](#)

[BrainHealth](#)

For partnerships in other parts of the portfolio, see [ERA Learn](#)



# Strategic documents relevant for R&I in EU

For further reading, not directly related to the health calls in HE.

- [EU competitiveness: Looking ahead - European Commission](#)
- [Enrico Letta - Much more than a market \(April 2024\)](#)
- [Align, act, accelerate - High Level Group presents recommendations on the future Framework Programme | European Research Area Platform](#)
- [Svenskt positionspapper inför EU:s nästa ramprogram för forskning och innovation, FP10 - Regeringen.se](#)